{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:17:03Z","timestamp":1791433023063,"version":"4.3.3"},"reference-count":187,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Else-Kr\u00f6ner-Fresenius-Stiftung","award":["Excellence Stipend to Paul J. Br\u00f6ckelmann"],"award-info":[{"award-number":["Excellence Stipend to Paul J. Br\u00f6ckelmann"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,10,24]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>The treatment landscape for lymphoma and multiple myeloma, which disproportionally affect older adults, has been transformed by the advent of T cell-mediated immunotherapies, including immune checkpoint inhibition, T cell-engaging bispecific antibodies, and chimeric antigen receptor (CAR) T cell therapy, during the last decade. These treatment modalities re-enable the patient\u2019s own immune system to combat malignant cells and offer the potential for sustained remissions and cure for various diseases.<\/jats:p>\n                  <jats:p>Age profoundly affects the physiological function of the immune system. The process of biological aging is largely driven by inflammatory signaling, which is reciprocally fueled by aging-related alterations of physiology and metabolism. In the T cell compartment, aging contributes to T cell senescence and exhaustion, increased abundance of terminally differentiated cells, a corresponding attrition in na\u00efve T cell numbers, and a decrease in the breadth of the receptor repertoire. Furthermore, inflammatory signaling drives aging-related pathologies and contributes to frailty in older individuals. Thus, there is growing evidence of biological aging modulating the efficacy and toxicity of T cell-mediated immunotherapies.<\/jats:p>\n                  <jats:p>Here, we review the available evidence from biological and clinical studies focusing on the relationship between T cell-mediated treatment of hematologic malignancies and age. We discuss biological features potentially impacting clinical outcomes in various scenarios, and potential strategies to improve the safety and efficacy of immune checkpoint inhibitors, T cell-engaging bispecific antibodies, and CAR-T cell therapy in older patients.<\/jats:p>","DOI":"10.1136\/jitc-2024-009462","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T07:35:12Z","timestamp":1733124912000},"page":"e009462","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03677154","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Fabian","family":"Ullrich","sequence":"first","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (DKTK partner site Essen), University Duisburg-Essen, University Hospital Essen, Essen, Nordrhein-Westfalen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9662-9900","authenticated-orcid":false,"given":"Paul J","family":"Br\u00f6ckelmann","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf (CIO ABCD) and German Hodgkin Study Group (GHSG), University of Cologne, Cologne, Germany"},{"name":"Max Planck Institute for Biology of Ageing, Cologne, Nordrhein-Westfalen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin T","family":"Turki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Marien Hospital Herne, Herne, Nordrhein-Westfalen, Germany"},{"name":"Institute for Artificial Intelligence in Medicine, University Duisburg-Essen, University Hospital Essen, Essen, Nordrhein-Westfalen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah M","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena-Diana","family":"Chiru","sequence":"additional","affiliation":[{"name":"Cancer Center Baselland, University of Basel Faculty of Medicine, Basel, Liestal, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Vetter","sequence":"additional","affiliation":[{"name":"Cancer Center Baselland, University of Basel Faculty of Medicine, Basel, Liestal, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian von","family":"Tresckow","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (DKTK partner site Essen), University Duisburg-Essen, University Hospital Essen, Essen, Nordrhein-Westfalen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Wirth","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Ruhr University Bochum, University Hospital Marien Hospital Herne, Herne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Cordoba","sequence":"additional","affiliation":[{"name":"Department of Hematology, Lymphoma Unit, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4699-6862","authenticated-orcid":false,"given":"Valent\u00edn","family":"Ortiz-Maldonado","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncoimmunotherapy Unit, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"F\u00fcl\u00f6p","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Geriatrics, Research Center on Aging, Universit\u00e9 de Sherbrooke, Sherbrooke, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8518-3616","authenticated-orcid":false,"given":"Nina Rosa","family":"Neuendorff","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Ruhr University Bochum, University Hospital Marien Hospital Herne, Herne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"2025100315265108000_12.12.e009462.1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(21)00179-3"},{"key":"2025100315265108000_12.12.e009462.2","doi-asserted-by":"crossref","first-page":"101734","DOI":"10.1016\/j.jgo.2024.101734","article-title":"Cellular therapies in older adults with hematological malignancies: a case-based, state-of-the-art review","volume":"15","author":"Neuendorff","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"2025100315265108000_12.12.e009462.3","doi-asserted-by":"crossref","first-page":"e736","DOI":"10.1016\/S2666-7568(21)00184-7","article-title":"Frailty assessment in the care of older people with haematological malignancies","volume":"2","author":"Goede","year":"2021","journal-title":"Lancet Healthy Longev"},{"key":"2025100315265108000_12.12.e009462.4","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1007\/s00277-023-05451-8","article-title":"Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians","volume":"102","author":"Dieterle","year":"2023","journal-title":"Ann Hematol"},{"key":"2025100315265108000_12.12.e009462.5","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.2022019536","article-title":"Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy","volume":"143","author":"Friedberg","year":"2024","journal-title":"Blood"},{"key":"2025100315265108000_12.12.e009462.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2017.10.024"},{"key":"2025100315265108000_12.12.e009462.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2016.12.008"},{"key":"2025100315265108000_12.12.e009462.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2016.09.005"},{"key":"2025100315265108000_12.12.e009462.9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1152\/physrev.00031.2021","article-title":"Trained immunity: adaptation within innate immune mechanisms","volume":"103","author":"Dom\u00ednguez-Andr\u00e9s","year":"2023","journal-title":"Physiol Rev"},{"key":"2025100315265108000_12.12.e009462.10","doi-asserted-by":"publisher","DOI":"10.1007\/s10522-015-9615-7"},{"key":"2025100315265108000_12.12.e009462.11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00982","article-title":"Immunobiography and the Heterogeneity of Immune Responses in the Elderly: A Focus on Inflammaging and Trained Immunity","volume":"8","author":"Franceschi","year":"2017","journal-title":"Front Immunol"},{"key":"2025100315265108000_12.12.e009462.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2006.11.016"},{"key":"2025100315265108000_12.12.e009462.13","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9010024","article-title":"B and T Cell Immunity in Tissues and Across the Ages","volume":"9","author":"Booth","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2025100315265108000_12.12.e009462.14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s43587-022-00198-9","article-title":"Multidimensional single-cell analysis of human peripheral blood reveals characteristic features of the immune system landscape in aging and frailty","volume":"2","author":"Luo","year":"2022","journal-title":"Nat Aging"},{"key":"2025100315265108000_12.12.e009462.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.03.010"},{"key":"2025100315265108000_12.12.e009462.16","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15770"},{"key":"2025100315265108000_12.12.e009462.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2005.00256.x"},{"key":"2025100315265108000_12.12.e009462.18","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100315265108000_12.12.e009462.19","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1158\/2326-6066.CIR-23-0121","article-title":"Considerations and Approaches for Cancer Immunotherapy in the Aging Host","volume":"11","author":"Ontiveros","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"2025100315265108000_12.12.e009462.20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature New Biol"},{"key":"2025100315265108000_12.12.e009462.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-01973-5","article-title":"The senescence journey in cancer immunoediting","volume":"23","author":"Zingoni","year":"2024","journal-title":"Mol Cancer"},{"key":"2025100315265108000_12.12.e009462.22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15245835","article-title":"Implications of Senescent T Cells for Cancer Immunotherapy","volume":"15","author":"Kasamatsu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025100315265108000_12.12.e009462.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00668-4"},{"key":"2025100315265108000_12.12.e009462.24","doi-asserted-by":"crossref","first-page":"101671","DOI":"10.1016\/j.jgo.2023.101671","article-title":"Senotherapy, cancer, and aging","volume":"15","author":"Balducci","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"2025100315265108000_12.12.e009462.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-305X(97)00027-X"},{"key":"2025100315265108000_12.12.e009462.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408617"},{"key":"2025100315265108000_12.12.e009462.27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-631747"},{"key":"2025100315265108000_12.12.e009462.28","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1"},{"key":"2025100315265108000_12.12.e009462.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701719"},{"key":"2025100315265108000_12.12.e009462.30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024729"},{"key":"2025100315265108000_12.12.e009462.31","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000770"},{"key":"2025100315265108000_12.12.e009462.32","doi-asserted-by":"publisher","DOI":"10.1038\/S41586-018-0317-6"},{"key":"2025100315265108000_12.12.e009462.33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30626-X"},{"key":"2025100315265108000_12.12.e009462.34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-022-00773-8","article-title":"Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment","volume":"13","author":"von Beck","year":"2023","journal-title":"Blood Cancer J"},{"key":"2025100315265108000_12.12.e009462.35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.578848","article-title":"Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature","volume":"11","author":"Kelkka","year":"2020","journal-title":"Front Immunol"},{"key":"2025100315265108000_12.12.e009462.36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261002","article-title":"CD8+ cell somatic mutations in multiple sclerosis patients and controls-Enrichment of mutations in STAT3 and other genes implicated in hematological malignancies","volume":"16","author":"Valori","year":"2021","journal-title":"PLoS One"},{"key":"2025100315265108000_12.12.e009462.37","doi-asserted-by":"publisher","DOI":"10.1007\/s10522-017-9682-z"},{"key":"2025100315265108000_12.12.e009462.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2018.10.011"},{"key":"2025100315265108000_12.12.e009462.39","doi-asserted-by":"crossref","DOI":"10.1016\/j.gore.2022.101018","article-title":"Etiopathogenesis of ovarian cancer. An inflamm-aging entity?","volume":"42","author":"S\u00e1nchez-Prieto","year":"2022","journal-title":"Gynecol Oncol Rep"},{"key":"2025100315265108000_12.12.e009462.40","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-3681-2_2"},{"key":"2025100315265108000_12.12.e009462.41","doi-asserted-by":"publisher","DOI":"10.1038\/nri1936"},{"key":"2025100315265108000_12.12.e009462.42","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3390\/ijms20112810","article-title":"The Evolving Role of CD8+CD28\u2212 Immunosenescent T Cells in Cancer Immunology","volume":"20","author":"Huff","year":"2019","journal-title":"IJMS"},{"key":"2025100315265108000_12.12.e009462.43","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: molecular mechanisms and diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"2025100315265108000_12.12.e009462.44","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0142-8"},{"key":"2025100315265108000_12.12.e009462.45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1040-8428(01)00168-8","article-title":"The unexpected contribution of immunosenescence to the leveling off of cancer incidence and mortality in the oldest old","volume":"39","author":"Bonaf\u00e8","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025100315265108000_12.12.e009462.46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00316","article-title":"Phenotype of NK-Like CD8(+) T Cells with Innate Features in Humans and Their Relevance in Cancer Diseases","volume":"8","author":"Barbarin","year":"2017","journal-title":"Front Immunol"},{"key":"2025100315265108000_12.12.e009462.47","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1706169"},{"key":"2025100315265108000_12.12.e009462.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.478"},{"key":"2025100315265108000_12.12.e009462.49","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578"},{"key":"2025100315265108000_12.12.e009462.50","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"2025100315265108000_12.12.e009462.51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1"},{"key":"2025100315265108000_12.12.e009462.52","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41392-023-01659-2","article-title":"Characteristics of premanufacture CD8+ T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma","volume":"8","author":"Wang","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"2025100315265108000_12.12.e009462.53","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01959-0"},{"key":"2025100315265108000_12.12.e009462.54","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01916-x"},{"key":"2025100315265108000_12.12.e009462.55","doi-asserted-by":"crossref","first-page":"101840","DOI":"10.1016\/j.smim.2023.101840","article-title":"Beyond youth: understanding CAR T cell fitness in the context of immunological aging","volume":"70","author":"Noll","year":"2023","journal-title":"Semin Immunol"},{"key":"2025100315265108000_12.12.e009462.56","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11893-4","article-title":"Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56","volume":"10","author":"Zou","year":"2019","journal-title":"Nat Commun"},{"key":"2025100315265108000_12.12.e009462.57","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"2025100315265108000_12.12.e009462.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"2025100315265108000_12.12.e009462.59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2025100315265108000_12.12.e009462.60","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"The Lancet"},{"key":"2025100315265108000_12.12.e009462.61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"2025100315265108000_12.12.e009462.62","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"2025100315265108000_12.12.e009462.63","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.clml.2020.05.008","article-title":"Real World Outcomes in Patients With Relapsed\/Refractory Diffuse Large B-cell Lymphoma Receiving Palliative Intent Therapies","volume":"20","author":"Ayers","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025100315265108000_12.12.e009462.64","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025100315265108000_12.12.e009462.65","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","article-title":"Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial","volume":"29","author":"Houot","year":"2023","journal-title":"Nat Med"},{"key":"2025100315265108000_12.12.e009462.66","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","article-title":"Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry","volume":"7","author":"Lemoine","year":"2023","journal-title":"Blood Adv"},{"key":"2025100315265108000_12.12.e009462.67","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"key":"2025100315265108000_12.12.e009462.68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"2025100315265108000_12.12.e009462.69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"2025100315265108000_12.12.e009462.70","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jtct.2023.03.012","article-title":"Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma","volume":"29","author":"Reyes","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2025100315265108000_12.12.e009462.71","doi-asserted-by":"crossref","first-page":"101628","DOI":"10.1016\/j.jgo.2023.101628","article-title":"Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: a systematic review and meta-analysis","volume":"15","author":"Akhtar","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"2025100315265108000_12.12.e009462.72","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"2025100315265108000_12.12.e009462.73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2301292"},{"key":"2025100315265108000_12.12.e009462.74","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/56.3.M146"},{"key":"2025100315265108000_12.12.e009462.75","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/jcsm.13118","article-title":"Frailty is characterized by biomarker patterns reflecting inflammation or muscle catabolism in multi-morbid patients","volume":"14","author":"Kochlik","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2025100315265108000_12.12.e009462.76","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2019.243246","article-title":"Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed\/refractory large B-cell lymphoma","volume":"106","author":"Lin","year":"2021","journal-title":"Haematologica"},{"key":"2025100315265108000_12.12.e009462.77","first-page":"12052","article-title":"Association of frailty and high-risk immuno-nutritional score with outcomes in patients with relapsed and refractory multiple myeloma treated with chimeric antigen receptor T-cells","volume":"41","author":"Modi","year":"2023","journal-title":"J C O"},{"key":"2025100315265108000_12.12.e009462.78","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3324\/haematol.2021.278288","article-title":"Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study","volume":"107","author":"Ram","year":"2022","journal-title":"Haematologica"},{"key":"2025100315265108000_12.12.e009462.79","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjh.18054","article-title":"Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma","volume":"197","author":"Roy","year":"2022","journal-title":"Br J Haematol"},{"key":"2025100315265108000_12.12.e009462.80","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1158\/2326-6066.CIR-22-0487","article-title":"Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy","volume":"11","author":"Rejeski","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"2025100315265108000_12.12.e009462.81","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jnci\/djy231","article-title":"Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation","volume":"111","author":"Armenian","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2025100315265108000_12.12.e009462.82","doi-asserted-by":"crossref","first-page":"373","DOI":"10.6004\/jnccn.2022.7100","article-title":"Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy","volume":"21","author":"Lee","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2025100315265108000_12.12.e009462.83","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.3390\/cells12212551","article-title":"The Influence of Obesity on Outcomes with Immune Checkpoint Blockade: Clinical Evidence and Potential Biological Mechanisms","volume":"12","author":"Hahn","year":"2023","journal-title":"Cells"},{"key":"2025100315265108000_12.12.e009462.84","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005226","article-title":"Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study","volume":"10","author":"Lee","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100315265108000_12.12.e009462.85","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/bloodadvances.2021005747","article-title":"Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment","volume":"6","author":"Teipel","year":"2022","journal-title":"Blood Adv"},{"key":"2025100315265108000_12.12.e009462.86","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/2643-3230.BCD-21-0177","article-title":"Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma","volume":"3","author":"Saini","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"2025100315265108000_12.12.e009462.87","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004554"},{"key":"2025100315265108000_12.12.e009462.88","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000957","article-title":"Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients","volume":"7","author":"Panagiota","year":"2023","journal-title":"Hemasphere"},{"key":"2025100315265108000_12.12.e009462.89","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044362"},{"key":"2025100315265108000_12.12.e009462.90","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4"},{"key":"2025100315265108000_12.12.e009462.91","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41409-022-01867-4","article-title":"Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA\/DRST experience","volume":"58","author":"Dreger","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"2025100315265108000_12.12.e009462.92","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1200\/JCO.23.02232","article-title":"Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed\/Refractory Multiple Myeloma","volume":"42","author":"Gagelmann","year":"2024","journal-title":"JCO"},{"key":"2025100315265108000_12.12.e009462.93","first-page":"7044","article-title":"Factors associated with manufacturing failure of commercial CD19 CAR-T cell products for large b cell lymphoma (LBCL)","volume":"42","author":"Patel","year":"2024","journal-title":"J C O"},{"key":"2025100315265108000_12.12.e009462.94","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jtct.2023.12.015","article-title":"Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed\/Refractory Multiple Myeloma","volume":"30","author":"Davis","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025100315265108000_12.12.e009462.95","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"2025100315265108000_12.12.e009462.96","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00159-6"},{"key":"2025100315265108000_12.12.e009462.97","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00931"},{"key":"2025100315265108000_12.12.e009462.98","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025100315265108000_12.12.e009462.99","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/01.HS9.0000847372.57687.d4","article-title":"P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND \u226565 YEARS WITH RELAPSED\/REFRACTORY FOLLICULAR LYMPHOMA AND \u22652 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY","volume":"6","author":"Matasar","year":"2022","journal-title":"HemaSphere"},{"key":"2025100315265108000_12.12.e009462.100","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv"},{"key":"2025100315265108000_12.12.e009462.101","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1182\/blood-2022-157768","article-title":"Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly\/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"140","author":"Olszewski","year":"2022","journal-title":"Blood"},{"key":"2025100315265108000_12.12.e009462.102","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"2025100315265108000_12.12.e009462.103","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100315265108000_12.12.e009462.104","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-177588","article-title":"Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit\/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"142","author":"Olszewski","year":"2023","journal-title":"Blood"},{"key":"2025100315265108000_12.12.e009462.105","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2203478"},{"key":"2025100315265108000_12.12.e009462.106","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"2025100315265108000_12.12.e009462.107","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"2025100315265108000_12.12.e009462.108","first-page":"308","article-title":"Safety and Efficacy of Teclistamab in Patients with Relapsed\/Refractory Multiple Myeloma: a Real-World Experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025100315265108000_12.12.e009462.109","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121861","article-title":"Cachexia and Sarcopenia in Older Adults with Cancer: a Comprehensive Review","volume":"11","author":"Dunne","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2025100315265108000_12.12.e009462.110","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.008"},{"key":"2025100315265108000_12.12.e009462.111","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood.2023022823","article-title":"Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"144","author":"Cortes-Selva","year":"2024","journal-title":"Blood"},{"key":"2025100315265108000_12.12.e009462.112","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/bloodadvances.2023011225","article-title":"CD8 effector T cells enhance teclistamab response in BCMA-exposed and -na\u00efve multiple myeloma","volume":"8","author":"Firestone","year":"2024","journal-title":"Blood Adv"},{"key":"2025100315265108000_12.12.e009462.113","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0038"},{"key":"2025100315265108000_12.12.e009462.114","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"2025100315265108000_12.12.e009462.115","unstructured":"Available: www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/hodgkin-lymphoma\/incidence#heading-One [Accessed 14 Apr 2024]."},{"key":"2025100315265108000_12.12.e009462.116","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1942"},{"key":"2025100315265108000_12.12.e009462.117","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bjh.17793","article-title":"9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial","volume":"196","author":"Gerhard-Hartmann","year":"2022","journal-title":"Br J Haematol"},{"key":"2025100315265108000_12.12.e009462.118","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"2025100315265108000_12.12.e009462.119","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025100315265108000_12.12.e009462.120","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0201"},{"key":"2025100315265108000_12.12.e009462.121","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1182\/blood.2020008553","article-title":"Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1","volume":"136","author":"Reinke","year":"2020","journal-title":"Blood"},{"key":"2025100315265108000_12.12.e009462.122","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1006-1"},{"key":"2025100315265108000_12.12.e009462.123","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41375-021-01421-z","article-title":"Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma","volume":"36","author":"Garcia-Marquez","year":"2022","journal-title":"Leukemia"},{"key":"2025100315265108000_12.12.e009462.124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101931"},{"key":"2025100315265108000_12.12.e009462.125","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"2025100315265108000_12.12.e009462.126","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000324"},{"key":"2025100315265108000_12.12.e009462.127","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial","volume":"41","author":"Br\u00f6ckelmann","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100315265108000_12.12.e009462.128","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3303"},{"key":"2025100315265108000_12.12.e009462.129","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"key":"2025100315265108000_12.12.e009462.130","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"key":"2025100315265108000_12.12.e009462.131","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hon.3163_5","article-title":"NIVOLUMAB(N)\u2010AVD IMPROVES PROGRESSION\u2010FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)\u2010AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826","volume":"41","author":"Herrera","year":"2023","journal-title":"Hematol Oncol"},{"key":"2025100315265108000_12.12.e009462.132","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-180114","article-title":"Nivolumab-AVD Is Better Tolerated and Improves Progression-Free Survival Compared to Bv-AVD in Older Patients (Aged \u226560 Years) with Advanced Stage Hodgkin Lymphoma Enrolled on SWOG S1826","volume":"142","author":"Rutherford","year":"2023","journal-title":"Blood"},{"key":"2025100315265108000_12.12.e009462.133","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/hon.3163_107","article-title":"PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DACARBAZINE (N\u2010AVD) AS FRONTLINE THERAPY IN OLDER ADULTS WITH HODGKIN LYMPHOMA","volume":"41","author":"Torka","year":"2023","journal-title":"Hematol Oncol"},{"key":"2025100315265108000_12.12.e009462.134","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-147863","article-title":"Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study","volume":"138","author":"Lazarovici","year":"2021","journal-title":"Blood"},{"key":"2025100315265108000_12.12.e009462.135","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet Haematol"},{"key":"2025100315265108000_12.12.e009462.136","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.132761"},{"key":"2025100315265108000_12.12.e009462.137","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/ijc.31763","article-title":"Senescence markers: Predictive for response to checkpoint inhibitors","volume":"144","author":"Moreira","year":"2019","journal-title":"Intl Journal of Cancer"},{"key":"2025100315265108000_12.12.e009462.138","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1420"},{"key":"2025100315265108000_12.12.e009462.139","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0203"},{"key":"2025100315265108000_12.12.e009462.140","doi-asserted-by":"crossref","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw"},{"key":"2025100315265108000_12.12.e009462.141","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1007\/s10238-023-01055-8","article-title":"Effect of age on the risk of immune-related adverse events in patients receiving immune checkpoint inhibitors","volume":"23","author":"Yang","year":"2023","journal-title":"Clin Exp Med"},{"key":"2025100315265108000_12.12.e009462.142","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jgo.2022.05.009","article-title":"Immune-related adverse events in older adults: data mining of the FDA Adverse Event Reporting System","volume":"13","author":"Chen","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"2025100315265108000_12.12.e009462.143","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","article-title":"Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study","volume":"7","author":"Nebhan","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025100315265108000_12.12.e009462.144","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2020.01.013","article-title":"Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies","volume":"129","author":"Baldini","year":"2020","journal-title":"Eur J Cancer"},{"key":"2025100315265108000_12.12.e009462.145","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.3390\/curroncol28050283","article-title":"Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study","volume":"28","author":"Paderi","year":"2021","journal-title":"Curr Oncol"},{"key":"2025100315265108000_12.12.e009462.146","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinMed"},{"key":"2025100315265108000_12.12.e009462.147","doi-asserted-by":"crossref","first-page":"101742","DOI":"10.1016\/j.jgo.2024.101742","article-title":"Immunotherapy use in older adults with cancer with frailty: a young SIOG review paper","volume":"15","author":"Guven","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"2025100315265108000_12.12.e009462.148","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jgo.2019.07.005","article-title":"Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: the Wilmot Cancer Institute experience","volume":"11","author":"Archibald","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"2025100315265108000_12.12.e009462.149","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100042","article-title":"A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study","volume":"6","author":"Gomes","year":"2021","journal-title":"ESMO Open"},{"key":"2025100315265108000_12.12.e009462.150","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0"},{"key":"2025100315265108000_12.12.e009462.151","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596"},{"key":"2025100315265108000_12.12.e009462.152","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"2025100315265108000_12.12.e009462.153","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020"},{"key":"2025100315265108000_12.12.e009462.154","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"2025100315265108000_12.12.e009462.155","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"2025100315265108000_12.12.e009462.156","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-173873","article-title":"Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7","volume":"142","author":"Kersten","year":"2023","journal-title":"Blood"},{"key":"2025100315265108000_12.12.e009462.157","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1097\/01.HS9.0000851292.41035.e8","article-title":"PB2115: TRIAL IN PROGRESS: A RANDOMIZED PHASE II STUDY OF MB-CART2019.1 COMPARED TO STANDARD OF CARE THERAPY IN PATIENTS WITH RELAPSED\/REFRACTORY DLBCL INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION","volume":"6","author":"Borchmann","year":"2022","journal-title":"HemaSphere"},{"key":"2025100315265108000_12.12.e009462.158","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2021014375","article-title":"Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma","volume":"140","author":"Ghione","year":"2022","journal-title":"Blood"},{"key":"2025100315265108000_12.12.e009462.159","first-page":"581","article-title":"Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2025100315265108000_12.12.e009462.160","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-179387","article-title":"Durable Efficacy and Manageable Safety in Patients Age \u2265 75 Years with Relapsed\/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting","volume":"142","author":"Landsburg","year":"2023","journal-title":"Blood"},{"key":"2025100315265108000_12.12.e009462.161","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015209"},{"key":"2025100315265108000_12.12.e009462.162","doi-asserted-by":"crossref","first-page":"E427","DOI":"10.1002\/ajh.26330","article-title":"Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel","volume":"96","author":"Wudhikarn","year":"2021","journal-title":"Am J Hematol"},{"key":"2025100315265108000_12.12.e009462.163","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174334","article-title":"The Dutch CAR-T Tumorboard Experience: population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands","volume":"15","author":"Spanjaart","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025100315265108000_12.12.e009462.164","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184671","article-title":"Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): a Single-Institution Experience","volume":"15","author":"Trando","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025100315265108000_12.12.e009462.165","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164028","article-title":"Predictive Factors of Response to Immunotherapy in Lymphomas: a Multicentre Clinical Data Warehouse Study (PRONOSTIM)","volume":"15","author":"Detroit","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025100315265108000_12.12.e009462.166","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01969-y"},{"key":"2025100315265108000_12.12.e009462.167","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"2025100315265108000_12.12.e009462.168","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"2025100315265108000_12.12.e009462.169","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100315265108000_12.12.e009462.170","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175"},{"key":"2025100315265108000_12.12.e009462.171","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"2025100315265108000_12.12.e009462.172","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00072-2"},{"key":"2025100315265108000_12.12.e009462.173","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1182\/bloodadvances.2023010840","article-title":"Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study","volume":"7","author":"Olszewski","year":"2023","journal-title":"Blood Adv"},{"key":"2025100315265108000_12.12.e009462.174","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat Med"},{"key":"2025100315265108000_12.12.e009462.175","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/hon.3174","article-title":"Glofitamab in relapsed\/refractory diffuse large B-cell lymphoma: Real-world data","volume":"41","author":"Birtas Atesoglu","year":"2023","journal-title":"Hematol Oncol"},{"key":"2025100315265108000_12.12.e009462.176","doi-asserted-by":"crossref","unstructured":"Maurer MJ , Casulo C , Larson MC , et al . Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma. haematol 2023. doi:10.3324\/haematol.2023.283737","DOI":"10.3324\/haematol.2023.283737"},{"key":"2025100315265108000_12.12.e009462.177","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/cncr.35217","article-title":"Glofitamab as a salvage treatment for B\u2010cell lymphomas in the real world: a multicenter study in Taiwan","volume":"130","author":"Hsu","year":"2024","journal-title":"Cancer"},{"key":"2025100315265108000_12.12.e009462.178","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1080\/10428194.2023.2262066","article-title":"Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed\/refractory follicular lymphoma in third or subsequent lines of systemic therapy","volume":"64","author":"McGough","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"2025100315265108000_12.12.e009462.179","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02657"},{"key":"2025100315265108000_12.12.e009462.180","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen \u00d7 CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"40","author":"D\u2019Souza","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025100315265108000_12.12.e009462.181","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"2025100315265108000_12.12.e009462.182","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"2025100315265108000_12.12.e009462.183","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s12325-023-02738-0","article-title":"Comparative Effectiveness of Teclistamab Versus Real-World Physician\u2019s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma","volume":"41","author":"Moreau","year":"2024","journal-title":"Adv Ther"},{"key":"2025100315265108000_12.12.e009462.184","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2022-0186","article-title":"Teclistamab versus real-world physician\u2019s choice of therapy in triple-class exposed relapsed\/refractory multiple myeloma","volume":"12","author":"Krishnan","year":"2023","journal-title":"J Comp Eff Res"},{"key":"2025100315265108000_12.12.e009462.185","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1007\/s12325-024-02797-x","article-title":"Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed\/Refractory Multiple Myeloma","volume":"41","author":"Einsele","year":"2024","journal-title":"Adv Ther"},{"key":"2025100315265108000_12.12.e009462.186","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/03007995.2023.2277850","article-title":"A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician\u2019s choice of treatment in patients with triple-class exposed\/refractory multiple myeloma","volume":"40","author":"Mol","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"2025100315265108000_12.12.e009462.187","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/fon-2023-0995","article-title":"Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma","volume":"20","author":"Costa","year":"2024","journal-title":"Fut Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:27:08Z","timestamp":1759530428000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":187,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,2]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/jitc-2024-009462"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009462","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}